Krystal Biotech, Inc. (KRYS)
Creates genetic medicines to treat rare skin and genetic diseases.
$364.23+0.04%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+132.0%
The outlook
KRYS trades at $364.23 and sits near its 52-week highs, above both its 50- and 200-day moving averages. Analysts overwhelmingly favor the stock with a Strong Buy consensus, though the average price target sits roughly 3% above the current price. The high valuation multiple reflects strong investor optimism.
What’s behind the score
Analyst consensusStrong Buy — 1.2 avg of 8 analysts
Price trendAbove its 50- & 200-day averages
52-week range93% of the way from its 52-week low to high
Price targetAvg target +3% vs current price
Analyst price target
~12-month · 8 analysts$376.75average target+3.4% vs now
Now $364.23
Low $284.00High $474.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$10.74B
52-wk high
$382.54
52-wk low
$130.50
50-day avg
$332.80
200-day avg
$268.50
Trailing P/E
48.8